Abelacimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | Factor XI and its active form Factor XIa |
| Clinical data | |
| Other names | MAA868 |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Intravenous |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| KEGG | |
Abelacimab (MAA868), is a fully human monoclonal antibody for the treatment of coagulation,[1] under developement by Anthos Therapeutics.
Mechanism of action
It is anti-factor XI antibody.[1][2]
See also
References
- 1 2 Verhamme P, Yi BA, Segers A, Salter J, Bloomfield D, Büller HR, et al. (August 2021). "Abelacimab for Prevention of Venous Thromboembolism". The New England Journal of Medicine. 385 (7): 609–617. doi:10.1056/NEJMoa2105872. PMID 34297496. S2CID 236198598.
- ↑ "Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC (Direct Oral Anticoagulant)". Business Wire. 18 September 2023.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.